SymBio Pharmaceuticals Limited (4582.T)
JPY 212.0
(-1.85%)
JPY 212.0
(-1.85%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -194.68 Million | 1.61 Billion | 140.04 Million | -4.12 Billion | -4.35 Billion | -2.32 Billion |
| Net Income | -1.96 Billion | 2.1 Billion | 1 Billion | -4.08 Billion | -4.37 Billion | -2.74 Billion |
| Depreciation & Amortization | 96 Million | 98.09 Million | 93.95 Million | 63.83 Million | 38.08 Million | 34.69 Million |
| Deferred income taxes | 1.08 Billion | - | -26.75 Million | 483.94 Million | 80.1 Million | 50.58 Million |
| Stock-based compensation | 82.49 Million | 104.73 Million | 124.27 Million | 102.37 Million | 127.14 Million | 122.94 Million |
| Change in working capital | 839.34 Million | -59.78 Million | -1.06 Billion | -228.53 Million | -241.71 Million | 184.36 Million |
| Other non-cash items | -337.66 Million | -635.08 Million | 13.9 Million | -457.69 Million | 18.1 Million | 31.58 Million |
| Investing Cash Flow | -376.69 Million | -47.12 Million | -70.84 Million | -160.3 Million | -216.46 Million | -26.18 Million |
| Investments in PPE | -232.79 Million | -47.55 Million | -63.83 Million | -148.93 Million | -216.51 Million | -39.76 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -143.89 Million | 431 Thousand | -7.01 Million | -11.37 Million | 49 Thousand | 13.58 Million |
| Financing Cash Flow | 680.16 Million | 627.98 Million | -71.92 Million | 4.22 Billion | 3.74 Billion | 4.27 Billion |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -996 Thousand | -48 Million | -72.82 Million | -33.67 Million | -32.45 Million | -29.75 Million |
| Common Stock Issuance | 681.15 Million | 662.22 Million | 903 Thousand | 4.24 Billion | 3.77 Billion | 4.27 Billion |
| Other Financing Activities | -1000.00 | 13.76 Million | 1000.00 | 10.53 Million | 3.74 Billion | 23.09 Million |
| Accounts receivables | 1.17 Billion | 62.59 Million | -1.74 Billion | 102.85 Million | -288.02 Million | 51.74 Million |
| Accounts payables | -46.63 Million | -23.05 Million | -595.77 Million | 544.54 Million | -605.18 Million | 121.71 Million |
| Inventory | 237.27 Million | -82.74 Million | 559.23 Million | -944.44 Million | 533.82 Million | -171.31 Million |
| Other working capital | -523.12 Million | -16.57 Million | 710.39 Million | 68.51 Million | 117.66 Million | 355.67 Million |
| Cash at beginning of period | 6.28 Billion | 3.86 Billion | 3.84 Billion | 3.91 Billion | 4.82 Billion | 2.94 Billion |
| Cash at end of period | 6.51 Billion | 6.28 Billion | 3.86 Billion | 3.84 Billion | 3.91 Billion | 4.82 Billion |
| Capital Expenditure | -232.79 Million | -47.55 Million | -63.83 Million | -148.93 Million | -216.51 Million | -39.76 Million |
| Effect of forex changes on cash | 125.67 Million | 213.71 Million | 14.2 Million | -1.5 Million | -83.37 Million | -47.03 Million |
| Net cash flow / Change in cash | 234.45 Million | 2.42 Billion | 11.48 Million | -62.2 Million | -910.52 Million | 1.87 Billion |
| Free Cash Flow | -427.48 Million | 1.56 Billion | 76.2 Million | -4.27 Billion | -4.56 Billion | -2.36 Billion |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -763.94 Million | -777 Million | -1.96 Billion | -1.17 Billion | -709 Million | -83 Million |
| Depreciation & Amortization | - | - | 96 Million | 23.83 Million | 23.78 Million | 23.85 Million |
| Deferred income taxes | - | - | 1.08 Billion | - | - | - |
| Stock-based compensation | 50.21 Million | - | 82.49 Million | - | - | - |
| Change in working capital | - | - | 839.34 Million | - | - | - |
| Other non-cash items | 713.73 Million | 777 Million | -337.66 Million | 1.17 Billion | 709 Million | 83 Million |
| Investing Cash Flow | - | - | -376.69 Million | - | - | - |
| Investments in PPE | - | - | -232.79 Million | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -143.89 Million | - | - | - |
| Financing Cash Flow | - | - | 680.16 Million | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -996 Thousand | - | - | - |
| Common Stock Issuance | - | - | 681.15 Million | - | - | - |
| Other Financing Activities | - | - | -1000.00 | - | - | - |
| Accounts receivables | - | - | 1.17 Billion | - | - | - |
| Accounts payables | - | - | -46.63 Million | - | - | - |
| Inventory | - | - | 237.27 Million | - | - | - |
| Other working capital | - | - | -523.12 Million | - | - | - |
| Cash at beginning of period | - | - | 6.28 Billion | 6.11 Billion | 6.07 Billion | 5.93 Billion |
| Cash at end of period | - | - | 6.51 Billion | 6.51 Billion | 6.11 Billion | 6.07 Billion |
| Capital Expenditure | - | - | -232.79 Million | - | - | - |
| Effect of forex changes on cash | - | - | 125.67 Million | - | - | - |
| Net cash flow / Change in cash | - | - | 234.45 Million | 402.14 Million | 38.84 Million | 136.45 Million |
| Free Cash Flow | - | - | -427.48 Million | 47.66 Million | 47.56 Million | 47.71 Million |
0002
6330
COMPINFO
RBX
TARSF
AMCX